Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 5/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP3 | P08254 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929284 | 0.95 | EPHX1 (0.45) | EPHX1CA12CA1CA9LMNA | |
| SCHEMBL2565754 | 0.94 | CA14 (0.33) | EPHX1 | |
| SCHEMBL3359618 | 0.92 | EPHX1 (0.45) | EPHX1LMNAACHE | |
| SCHEMBL17828588 | 0.92 | EPHX1 (0.33) | EPHX1CA12CA1CA9LMNA | |
| SCHEMBL2616732 | 0.90 | EPHX1 (0.37) | EPHX1CA12CA9LMNAACHE | |
| SCHEMBL22574055 | 0.89 | CA12 (0.38) | EPHX1CA12CA1CA9LMNA | |
| SCHEMBL17133217 | 0.88 | EPHX1 (0.44) | EPHX1ACHE | |
| SCHEMBL17133208 | 0.88 | ACHE (0.35) | EPHX1LMNAACHEMMP2ALDH1A1 | |
| SCHEMBL21924930 | 0.88 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL13907613 | 0.85 | EPHX1 (0.34) | EPHX1LMNAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180066165-A1 | HIGH-SPEED MOISTURE-CURE HYBRID SILOXANE/SILSESQUIOXANE-URETHANE AND SILOXANE/SILSESQUIOXANE-EPOXY SYSTEMS WITH ADHESIVE PROPERTIES | GELEST, INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180066165-A1 | HIGH-SPEED MOISTURE-CURE HYBRID SILOXANE/SILSESQUIOXANE-URETHANE AND SILOXANE/SILSESQUIOXANE-EPOXY SYSTEMS WITH ADHESIVE PROPERTIES | PCNA, ICAM1, CCNO | EPHX1 46/4885CA12 500/4885CA1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.